Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like it. Market is being cautiously optimistic I think ahead of the data. 2 more days to see any pre data run up. I may actually hold my full position into data next week IMO. If data good, this will run big if no pre data run up. So there's that going for $QURE
All the GT's are down about the same percentage, just hoped the QURE would have some momo heading into data. Guess run-ups to data are the thing of the past.
QURE
I picked up a bunch in the 15.60s. Next week pay day
Unbelievable Quick Ratio:
Quick Ratio 9.20
Also great cash: Cash/sh 10.91
http://finviz.com/quote.ashx?t=qure
That of BMY is only 1.60 and Cash/sh 3.24
Can't be too much downside. Fiscally well managed.
QURE
Back in QURE this morning @ $15.82.
See Piper has new report:
_________________________________________________
Piper Jaffray Thinks uniQure NV’s Stock is Going to Recover
By George Macdonald
January 6, 2016 Top News 0 Comments
In a report released yesterday, Joshua Schimmer from Piper Jaffray maintained an Overweight rating on uniQure NV (NASDAQ: QURE), with a price target of $35. The company’s shares closed yesterday at $16.17, close to its 52-week low of $15.05.
Schimmer said, “As we kick off a new year, we are refreshing our thinking on our coverage universe. As a leader in the gene therapy field, QURE continues to evolve its path forward and hone its pipeline and capabilities. With a new CEO at the helm, the company will look to focus its efforts on advancing products to the market. We expect early results from its hemophilia B gene therapy program in 1Q16 and its San Filippo B gene therapy will move into pivotal testing later this year. QURE has an attractive toolkit of advanced vectors (partnership with 4D Molecular Therapeutics) and promoters (partnership with Sympronics) as well as large-scale manufacturing capabilities and a broad partnership with BMY. We look forward to strategic updates over the course of the year. “
uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $42.33.
Based on uniQure NV`s latest earnings report from September 30, the company posted quarterly revenue of $3.54M and quarterly net profit of -$29.08M. In comparison, last year the company earned revenue of $1.62M and had a net profit of -$12.2M.
According to TipRanks.com, Schimmer is ranked 0 out of 5 stars with an average return of -5.5% and a 37.1% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Bellicum Pharmaceuticals, and Voyager Therapeutics Inc.
uniQure NV is engaged in the field of gene therapy and has developed a gene therapy product to receive regulatory approval in the European Union.
______________________________________
http://www.analystratings.com/2016/01/06/piper-jaffray-thinks-uniqure-nvs-stock-is-going-to-recover/
QURE
She keeps losing any morning gains by mid day IMO
Will retest 15.40 again. It might be the last chance to get below 15.50.
Unless the market keep falling tomorrow.
I'm bidding for 15.30s as well but don't have hope of getting a fill. That's ok. I've got plenty in my stash already.
Seemed this sell off has ended. It is a pretty good entry point unless tomorrow we get another round. I suspect tomorrow will have at least rebound back to 16.00.
The free fall will stop at some point. I don't expect the sell off to cover more than 10%. It will definitely rebound when reach 10% fall. That will be a buy point for most of people who are seeking bottom.
JBEM sold some as well last trading day, he indicated on bob and JBEM's board.
He used the term TRIM.
It might get really tough to drop below 15.00.
15.10 might be more realistic. I am re-adjusting to 15.15 if not below 15.00 before 1:30 pm
I have it at 14.98 for another 1.2k. Sold half last day of the year at 16.25. Now loading with additional funds.
Had bid @ $15.10, but dropped it to $14.90 -- we'll see.
Buying more?
QURE
You might be able to get close to 15.00 today.
The thing I've seen about QURE is the after-hours trades. Have posted about the trades at about 4:06 to 4:12pm. A lot of times there is a trade which ends up not being adjusted later which drops the pps so that the day of profit is lost. Happened last Thurs. The biggest annoyance of trading is MMs which manipulate after hours.
QURE
Good trade. Looks like there might be a sell off today. You might just get what you want for a re-entry.
Nicely done. You may not get a nice dip IMO at least that's my theory which is why I held instead of booking some gains. She closed above EMA 10 like I hoped yesterday she would close today. Feel good about this one. Macd curling and RSI showing a nice angle with room to run here. Next stop break 17ish and then test MA50 at 18.16? IMO.
Sure was. Was just getting ready to post (like I usually do) that had sold @ $16.70 at about 3:50pm. Will be looking for re-entry as this is set to go up much more. Just that I follow the chart and that was my target from earlier in the day.
Saw 15 day MA as possible resistance:
Hope to get shares again the next dip.
Good luck with your trade.
QURE
Nice action and intraday b/o into the close. Nicely getting set up for Monday. Will run nicely IMO.
Steve Cohen of Point72 (driving CMRX today) and Joseph Edelman of Perceptive both have nice stakes in QURE -- as do the Baker Bros.
QURE
Was stupid to have posted Goldman info. Not news, but apparently attempt at manipulation since the "sell" was long ago:
J. GOLDMAN & CO LP 09/30/2015 27,874 (142,073) (83.6) 449
Read more: http://www.nasdaq.com/symbol/qure/institutional-holdings?page=2#ixzz3vvY4PXz4
QURE
J. Goldman & Company Sells 142,073 Shares of Uniqure NV (QURE)
December 31st, 2015 - By Doug Madison - 0 comments
Uniqure NV logoJ. Goldman & Company decreased its position in Uniqure NV (NASDAQ:QURE) by 83.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,874 shares of the company’s stock after selling 142,073 shares during the period. J. Goldman & Company owned 0.13% of Uniqure NV worth $570,000 at the end of the most recent reporting period.
Shares of Uniqure NV (NASDAQ:QURE) opened at 16.12 on Thursday. The firm’s market cap is $390.39 million. The firm has a 50-day moving average price of $18.11 and a 200-day moving average price of $23.17. Uniqure NV has a 52 week low of $14.67 and a 52 week high of $36.38.
Uniqure NV (NASDAQ:QURE) last issued its earnings results on Monday, November 30th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.50. On average, equities research analysts predict that Uniqure NV will post ($3.03) earnings per share for the current year.
A number of equities analysts have recently issued reports on the company. Roth Capital restated a “buy” rating and set a $38.00 price objective on shares of Uniqure NV in a research report on Monday, September 21st. Piper Jaffray reiterated a “buy” rating on shares of Uniqure NV in a report on Monday, September 21st. Oppenheimer lifted their target price on Uniqure NV from $47.00 to $50.00 and gave the stock an “outperform” rating in a report on Monday, September 21st. Leerink Swann reiterated an “outperform” rating and issued a $48.00 target price (up from $44.00) on shares of Uniqure NV in a report on Monday, September 21st. Finally, Chardan Capital reiterated a “buy” rating on shares of Uniqure NV in a report on Wednesday, September 16th. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $41.36.
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. The Company’s first product is Glybera, for the treatment of lipoprotein lipase deficiency (NASDAQ:QURE). In the clinical pipeline, it has gene treatments for hemophilia, porphyria, Parkinson, Sanfilippo B syndrome and hearing loss. Additionally, it is engaged in the development of therapies based on adeno-associated virus (AAV) through multiple collaborations. The Company uses modular technology platform, including a cost effective manufacturing process. In August 2014, Uniqure NV acquired InoCard GmbH, an early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.
_________________________________________________-
http://www.dakotafinancialnews.com/j-goldman-company-sells-142073-shares-of-uniqure-nv-qure/774360/
So what is it? Buys or sells? Need to check but don't see proof of either yet.
QURE
J. Goldman & Company Invests $2,922,000 in Uniqure NV (QURE)
Posted by Joseph Griffin on Dec 31st, 2015 // No Comments
Goldman & Company purchased a new position in Uniqure NV (NASDAQ:QURE) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The hedge fund purchased 142,900 shares of the company’s stock, valued at approximately $2,922,000.
Shares of Uniqure NV (NASDAQ:QURE) opened at 16.12 on Thursday. The stock’s market cap is $390.39 million. The company has a 50-day moving average price of $18.11 and a 200-day moving average price of $23.17. Uniqure NV has a 1-year low of $14.67 and a 1-year high of $36.38.
Uniqure NV (NASDAQ:QURE) last announced its quarterly earnings results on Monday, November 30th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.50. On average, equities analysts expect that Uniqure NV will post ($3.03) earnings per share for the current fiscal year.
QURE has been the topic of several recent research reports. Piper Jaffray restated an “overweight” rating and issued a $40.00 price target on shares of Uniqure NV in a research report on Friday, October 16th. Oppenheimer restated a “buy” rating on shares of Uniqure NV in a research report on Tuesday, September 22nd. Chardan Capital restated a “buy” rating on shares of Uniqure NV in a research report on Wednesday, September 16th. HC Wainwright reiterated a “buy” rating and set a $39.00 target price on shares of Uniqure NV in a research report on Thursday, September 24th. Finally, Roth Capital reiterated a “buy” rating and set a $38.00 target price on shares of Uniqure NV in a research report on Tuesday, September 8th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. Uniqure NV has an average rating of “Buy” and a consensus price target of $41.36.
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. The Company’s first product is Glybera, for the treatment of lipoprotein lipase deficiency (NASDAQ:QURE). In the clinical pipeline, it has gene treatments for hemophilia, porphyria, Parkinson, Sanfilippo B syndrome and hearing loss. Additionally, it is engaged in the development of therapies based on adeno-associated virus (AAV) through multiple collaborations. The Company uses modular technology platform, including a cost effective manufacturing process. In August 2014, Uniqure NV acquired InoCard GmbH, an early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.document.write(‘‘);
______________________________________________
http://www.tickerreport.com/banking-finance/1166289/j-goldman-company-invests-2922000-in-uniqure-nv-qure/
QURE
I hear you but check daily chart several 5-6 green day runs. This will happen again. That will be a running with strength scenario not hindered by artificial factors like holiday season pullback, tax loss selling, CEO change and this that and the other thing. IMO.
We will test 16.51 today. I will stick to my target zone and try not to sell them at once.
I know I will be gone way before. JBEM confirmed this morning still in. Don't believe $heff is in although he has several recent posts about QURE. I tend to trade more like $heff if I can. QURE doesn't run green for many days before pulling back.
QURE
I am sure JBEM will exit way before that for his play. $heff will be way earlier, because he is particular 10-20% gainer.
Although they might not announce it, but I do believe we will see a large portion of shares will be over sold and that might drive the pps down. $43 might be realistic within 2 years but not gonna be realistic for the short term momentum.
Sure hoping so. Darling of analysts:
____________________________________________________________
Consensus Ratings for Uniqure NV (NASDAQ:QURE)
Ratings Breakdown: 11 Buy Rating(s)
Consensus Rating: Buy (Score: 3.00)
Consensus Price Target: $43.40 (180.36% upside)
___________________________________________________________
http://www.marketbeat.com/stocks/NASDAQ/QURE/
QURE
Loaded another 800 shares at 15.67. It will go above $20.00 soon.
The target price will be $23.5 IMO.
It will break $20.00 soon.
Finally broke through $16.00 -- a good start!
QURE
Looks like it is ready for the next run up to at least 17 again.
Believe he is still holding and plans to hold thru data since data could be released without heads up. This will see upside into data since this has been so beaten up. Tax selling, CEO announcement and the usual shorts. All creating nice opportunity to load. I'm holding longer term glad he will not announce exit and put brakes on the run IMO
Only own bit over 1k shares but Definitely will hold half of that until end of 2016. This is another gem.
Don't know if JBEM still holding. Believe he will hold at least 1 day prior to the catalyst in Jan.
But JBEM will no longer announce his exit, so my target is $22-$25 zone.
Strong likelihood he is already loading. I'm locked and loaded with this mornings fill. Glty
I believe $heff will get on this one again or at least watch it closely. See his post.
142,900 Shares in Uniqure NV (QURE) Acquired by J. Goldman & Company
Posted by Kristian Gore on Dec 29th, 2015
Uniqure NV logoJ. Goldman & Company purchased a new position in Uniqure NV (NASDAQ:QURE) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The hedge fund purchased 142,900 shares of the company’s stock, valued at approximately $2,922,000.
Uniqure NV (NASDAQ:QURE) opened at 15.53 on Tuesday. The firm has a 50-day moving average price of $18.31 and a 200 day moving average price of $23.32. Uniqure NV has a 12 month low of $14.64 and a 12 month high of $36.38. The company’s market capitalization is $376.11 million.
Uniqure NV (NASDAQ:QURE) last posted its earnings results on Monday, November 30th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by $0.50. Analysts expect that Uniqure NV will post ($3.03) EPS for the current year.
A number of equities research analysts have recently weighed in on QURE shares. Roth Capital reaffirmed a “buy” rating on shares of Uniqure NV in a research note on Monday, August 31st. Chardan Capital reaffirmed a “buy” rating on shares of Uniqure NV in a research note on Wednesday, September 16th. Oppenheimer raised their price target on Uniqure NV from $47.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, September 21st. Piper Jaffray reaffirmed a “buy” rating on shares of Uniqure NV in a research note on Monday, September 21st. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $48.00 price target (up from $44.00) on shares of Uniqure NV in a research note on Monday, September 21st. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Uniqure NV currently has an average rating of “Buy” and an average target price of $41.36.
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. The Company’s first product is Glybera, for the treatment of lipoprotein lipase deficiency (NASDAQ:QURE). In the clinical pipeline, it has gene treatments for hemophilia, porphyria, Parkinson, Sanfilippo B syndrome and hearing loss. Additionally, it is engaged in the development of therapies based on adeno-associated virus (AAV) through multiple collaborations. The Company uses modular technology platform, including a cost effective manufacturing process. In August 2014, Uniqure NV acquired InoCard GmbH, an early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.
________________________________________________
http://www.wkrb13.com/markets/983557/142900-shares-in-uniqure-nv-qure-acquired-by-j-goldman-company/
QURE
Posted on TheFly last nite:
"uniQure volatility elevated into top-line hemophilia B data expected in 2016
uniQure January call option implied volatility is at 206, February is at 153; compared to its 52-week range of 72 to 175, suggesting large price movement into top-line hemophilia B data expected in early 2016."
QURE
Also bought some call 5.00 Jan 16 for .25 a share. If it goes above 6.00 before it expires it will triple the money I put in.
I exited before Christmas around 17.12 and 17.18 for half of my position loaded at 16.00. And loaded again at 15.53 today. Feeling pretty good. I am here long but love the short term play.
Hope so! Can't say down due to low volume -- almost double the 50 day vol average. Believe today is the last day for shorts to cover for tax loss selling. Maybe that is the reason for being down, as well as CMRX giving folks pause of early reporting of data before anticipated.
You're feeling good about you position?
QURE
Excellent enter point.
$QURE Piper Jaffray says CEO change has been in the works for a while and is in no way related to the upcoming hemophilia trial readout.
http://thefly.com/landingPageNews.php?id=2302861&headline=QURE-uniQure-CEO-change-not-related-to-hemophilia-readout-says-Piper-Jaffray
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
225
|
Created
|
04/06/15
|
Type
|
Free
|
Moderators |
uniQure N.V. (uniQure) is a gene therapy company. The Company is engaged in developing single treatments with curative results for patients suffering from genetic and other severe diseases. The Company is advancing a focused pipeline of gene therapies that have been developed both internally and through partnerships. The Company’s product candidates include AMT-060 for Hemophilia B, AMT-130 for Huntington's disease, S100A1 for congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). uniQure has established clinical proof-of-concept in its lead indication, hemophilia B and has achieved pre-clinical, proof-of-concept in Huntington's disease. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.
AMT-060 for Hemophilia B
AMT-060 is a gene therapy for the treatment of Hemophilia B. Hemophilia B is an inherited disease in males characterized by insufficient blood clotting. AMT-060 consists of the adeno-associated virus (AAV) vector carrying a human Factor IX (FIX) gene cassette that the Company has exclusively licensed from St. Jude Children’s Research Hospital in Memphis, Tennessee. The Company produces this vector with its insect cell-based manufacturing process. It has an ongoing Phase I/II clinical trials.
AMT-130 for Huntington's Disease
AMT-130 is developed for the treatment of Huntington's disease (HD). HD is caused by an inherited defect in a single gene that codes for protein called Huntingtin. The Company’s product candidate AMT-130 consists of an AAV5 vector carrying an artificial micro-RNA, which silences the Huntingtin gene. The therapeutic goal is to inhibit the production of the mutant protein.
S100A1 for Congestive Heart Faliure
The Company has entered into an agreement with BMS that provides exclusive access to the Company’s gene therapy technology platform for multiple targets in cardiovascular (and other) diseases (Collaboration and License Agreement). The collaboration includes its proprietary gene therapy program for congestive heart failure, which aims to restore the heart's ability to synthesize S100A1. . S100A1 is a calcium sensor and master regulator of heart function, and thereby improve clinical outcomes for patients with reduced ejection fraction. S100A1 deficient hearts show accelerated progression to severe heart failure and increase mortality after cardiac damage. The Company is leading the discovery, non-clinical, analytical and process development effort and is responsible for manufacturing of clinical and commercial supplies using our vector technologies and industrial, proprietary insect-cell based manufacturing platform, while BMS leads development and regulatory activities across all programs and is responsible for all research and development costs. BMS will be solely responsible for commercialization of all products from the collaboration.
Glybera for Lipoprotein Lipase Deficiency
Glybera is a gene therapy that is designed to restore the LPL enzyme activity required to enable the processing, or clearance, of fat-carrying chylomicron particles formed in the intestine after a fat-containing meal. The product consists of an engineered copy of the human LPL gene packaged with a tissue-specific promoter in a non-replicating AAV1 vector, which has a particular affinity for muscle cells. In order to improve activity, the Company uses a naturally occurring variant of the LPL gene that has higher enzyme activity than the normal version of the gene that encodes the protein. It produces Glybera using its insect cell-based manufacturing process. In the European Union, the Company has been granted orphan drug exclusivity for Glybera for treatment of LPLD until October 2022. The first commercial patient in Europe was treated with Glybera in September 2015.
Other Early-Stage Research
The Company is also engaged in the research of several other gene therapy candidates targeting rare and orphan diseases. It focuses on genetic diseases affecting the liver, including hemophilia A, as well as various central nervous system (CNS) disorders.
Vector Development
uniQure seeks to develop next-generation vectors with increased potency to target liver indications in which high relative percentage increases in the secretion of a protein above the disease state would be required for therapeutic benefit. These next-generation vectors may be used in the development of a gene therapy for hemophilia A as well as other therapeutic indications. In January 2014, the Company has entered into a collaboration and license agreement with 4D Molecular Therapeutics, LLC for the discovery and optimization of next-generation AAV vectors targeting the liver and the brain.
The Company competes with AGTC, Abeona Therapeutics, Adverum Biotechnologies, Asklepios BioPharmaceutical, Audentes Therapeutics, Avalanche Biotech, AveXis, Bayer, BioMarin, Bioveratiy, bluebird bio, Dimension Therapeutics, Errant Gene Therapeutics, Expression Therapeutics, Freeline Therapeutics, Genethon, Genzyme, GlaxoSmithKline, Homology Medicines, Lysogene, Megenics, Milo Therapeutics, Nightstarx, Pfizer, REGENXBIO, Renova Therapeutics, Retrosense Therapeutics, Sangamo BioSciences, Shire, Solid Biosciences, Spark Therapeutics, Takara, Voyager, Amgen, Bayer, Biogen, BioMarin, Genzyme, Novartis, Novo Nordisk, Pfizer, and Shire.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |